Zobrazeno 1 - 10
of 3 341
pro vyhledávání: '"glucagon like peptide 1 receptor"'
Autor:
Sina A. Gharib, Rachna Vemireddy, Joseph J. Castillo, Brendy S. Fountaine, Theo K. Bammler, James W. MacDonald, Rebecca L. Hull-Meichle, Sakeneh Zraika
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Insulin secretion is impaired in individuals with cystic fibrosis (CF), contributing to high rates of CF-related diabetes (CFRD) and substantially increasing disease burden. To develop improved therapies for CFRD, better knowledge of pancrea
Externí odkaz:
https://doaj.org/article/02eecb3558cb4daeb1a5360a32a28b02
Autor:
Mahmoud Balata, Marc Ulrich Becher
Publikováno v:
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background & objectives Obesity is a common comorbidity in heart failure, yet effective pharmacological options for weight loss in these patients are limited. Semaglutide, a glucagon-like peptide 1 receptor agonist, has shown promise for wei
Externí odkaz:
https://doaj.org/article/78c6c558cc3a4a8a977cc08ef214cfc7
Autor:
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1202-1210 (2024)
ABSTRACT Introduction Glucagon‐like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of th
Externí odkaz:
https://doaj.org/article/98534f7f8829407095660795b31ba776
Autor:
Cesare Berra, Roberto Manfrini, Francesco Bifari, Elisa Cipponeri, Renata Ghelardi, Lucia Centofanti, Umberto Mortola, Elena Lunati, Loredana Bucciarelli, Vincenzo Cimino, Franco Folli
Publikováno v:
Pharmacological Research, Vol 210, Iss , Pp 107517- (2024)
We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatien
Externí odkaz:
https://doaj.org/article/809d86e79ffb45e6b4dd60d82ba3bd1d
Autor:
Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis
Publikováno v:
Revista Mexicana de Endocrinología, Metabolismo y Nutrición, Vol 11, Iss 4 (2024)
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretin
Externí odkaz:
https://doaj.org/article/c25ef5cbde2849b68d042d5b5a2c69bd
Autor:
Yuki Oe, Hiroshi Nomoto, Kyu Yong Cho, Kei Yokozeki, Tsubasa Ono, Aika Miya, Hiraku Kameda, Akinobu Nakamura, Yoshiaki Arimura, Tatsuya Atsumi
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Oral semaglutide in older subjects with type 2 diabetes was as effective as in younger subjects, according to phase 3 clinical trials. However, its efficacy can be limited in very aged population, due to the presence of impaired c
Externí odkaz:
https://doaj.org/article/47768c8012034b3c807844e9992d4bf5
Autor:
Christopher S. Freet, Brianna Evans, Timothy R. Brick, Erin Deneke, Emily J. Wasserman, Sarah M. Ballard, Dean M. Stankoski, Lan Kong, Nazia Raja-Khan, Jennifer E. Nyland, Amy C. Arnold, Venkatesh Basappa Krishnamurthy, Julio Fernandez-Mendoza, H. Harrington Cleveland, Adam D. Scioli, Amanda Molchanow, Amy E. Messner, Hasan Ayaz, Patricia S. Grigson, Scott C. Bunce
Publikováno v:
Addiction Science & Clinical Practice, Vol 19, Iss 1, Pp 1-13 (2024)
Abstract Background Despite continuing advancements in treatments for opioid use disorder (OUD), continued high rates of relapse indicate the need for more effective approaches, including novel pharmacological interventions. Glucagon-like peptide 1 r
Externí odkaz:
https://doaj.org/article/85a4d926fdcd4c8dbbfc6c19cf3a5ca6
Publikováno v:
Diabetology, Vol 5, Iss 3, Pp 234-245 (2024)
The prevalence of obesity in adults with type 1 diabetes is increasing and reflects the rates of the general adult population. The coexistence of overweight or obesity and type 1 diabetes poses a major challenge to effective glycemic and weight manag
Externí odkaz:
https://doaj.org/article/69e29db473ed400fa9e56e2d64041b78
Autor:
Ronnakrit Trakoonsenathong, Waritta Kunprom, Chaiwat Aphivatanasiri, Padcharee Yueangchantuek, Paslada Pimkeeree, Supannika Sorin, Kullanat Khawkhiaw, Ching-Feng Chiu, Seiji Okada, Sopit Wongkham, Charupong Saengboonmee
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Glucagon-like peptide 1 receptor (GLP-1R) agonist is an emerging anti-diabetic medication whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial. This study aimed to elucidate the roles of GLP-1R and its agon
Externí odkaz:
https://doaj.org/article/3f829bc7a7884a4b8a49da98aa78d254
Publikováno v:
ESC Heart Failure, Vol 11, Iss 3, Pp 1647-1656 (2024)
Abstract Aims The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotrans
Externí odkaz:
https://doaj.org/article/5509a21845ba41ccb1191149c0c6d527